Health Canada open data (page 8)
Health Canada publishes 2,987 open datasets on CanQuery: 58 with live tables. Preview tables, export CSV and follow original downloads.
- Datasets
- 2987
- Queryable datasets
- 58
- Mappable datasets
- 0
Datasets
- Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)
- Summary Safety Review - Levetiracetam and Methotrexate - Assessing the Potential Risk of Drug-Drug Interaction
- Summary Safety Review - Lanoxin, Toloxin, Apo-digoxin, PMS-digoxin, (Digoxin) - Assessing the Potential Higher Risk of Death Compared to Patients not Using Digoxin
- Summary Safety Review - KEPPRA (levetiracetam) - Assessing the Potential Risk of Acute Kidney Injury (Acute renal failure/Interstitial nephritis)
- Summary Safety Review - INTUNIV XR (guanfacine hydrochloride) - Assessing the Potential Risk of Raynaud's Phenomenon
- Summary Safety Review - Intraocular lenses - Assessing the potential risk of developing small pockets of liquid in intraocular lenses (glistening)
- Summary Safety Review - Hydroxyzine (ATARAX and generics) - Assessing the Potential Risk of Abnormal Heart Rhythm
- Summary Safety Review - Hydrocodone-containing products - Assessing the Risk of Serious Breathing Problems (respiratory depression) in Children and Adolescents
- Summary Safety Review - Green tea extract-containing natural health products - Assessing the potential risk of liver injury (hepatotoxicity)
- Summary Safety Review - GARDASIL (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) - Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases
- Summary Safety Review - Gadolinium based contrast agents - Assessing the risk of gadolinium build-up in the brain and potential brain and nervous system (neurological) side effects
- Summary Safety Review - Gabapentin - Assessing the Potential Risk of Serious Breathing Problems
- Summary Safety Review - Fluoroquinolones - Assessing the potential risk of persistent and disabling side effects
- Summary Safety Review - Finasteride - Assessing the Potential Risk of Suicidal Thoughts and Behaviour (Suicidality)
- Summary Safety Review - Finasteride - Assessing the Potential Risk of Serious Muscle-Related Side Effects
- Summary Safety Review - EYLEA (aflibercept) - Assessing the Risk of Side Effects Outside the Eye (systemic side effects)
- Summary Safety Review - ABILIFY and ABILIFY MAINTENA (aripiprazole) - Evaluating the Risk of Certain Impulse Control Behaviours
- Summary Safety Review - Alpha Lipoic Acid - Assessing the Potential Risk of Low Blood Sugar (Hypoglycemic Episodes)
- Summary Safety Review - Antidepressants - Assessing the Potential Risk of Serious Eye Disorder (Angle-Closure Glaucoma)
- Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea
- Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of sleep walking and sleep-related eating disorder
- Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention
- Summary Safety Review - AUBAGIO (teriflunomide) - Assessing the potential risk of inflammation of the colon (colitis)
- Summary Safety Review - Benzodiazepines and barbiturates - Assessing the potential risk of negative effects on the development of children’s brains (neurodevelopmental disorders)
- Summary Safety Review - Bisphosphonates - Assessing the Potential Risk of Severe Bone Damage (osteonecrosis)
- Summary Safety Review - Breast Implants - Assessing the potential risk of cancer (Breast implant associated-anaplastic large cell lymphoma)
- Summary Safety Review - Celecoxib - Assessing the Risk of Serious Heart and Stroke Side Effects at High Doses Relative to Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Summary Safety Review - Clozapine - Assessing the effectiveness of monitoring for low numbers of white blood cells
- Summary Safety Review - CODEINE PRESCRIPTION PRODUCTS Indicated for Cough - Further Assessing the Risk of Serious Breathing Problems in Children and Adolescents
- Summary Safety Review - Codeine-containing products - Further Assessing the Risk of Serious Breathing Problems in Children and Adolescents
- Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness
- Summary Safety Review - DICLECTIN (doxylamine and pyridoxine combination) - Assessing Safety in pregnancy
- Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure
- Summary Safety Review - Ear and Forehead (contact) Infrared Thermometers (various brands) - Assessing the potential risk of inaccuracy in children under 2 years old
- Summary Safety Review - ESSURE Permanent Birth Control System - Assessing the Risk of Complications and the Potential Need for Device Removal
- Health Canada's Response to the Carlin Jury Recommendations Aimed at the Department or Directly Relevant to its Mandate
- Laser eye surgery
- Let's talk about acetaminophen
- Module 1: Overview of Vanessa’s Law and reporting requirements
- Module 2: Reporting processes to Health Canada
- Module 3: Strategies to promote and support mandatory reporting
- Module 4: Health Canada’s review and communication of safety findings
- Notice of clarification to drug manufacturers and sponsors - Risk Management Plans - Update
- Notice of clarification to drug manufacturers and sponsors: Canadian-specific considerations in risk management plans
- Optimizing the Use of Real World Evidence to Inform Regulatory Decision-Making
- Reporting adverse reactions to marketed health products - Guidance document for industry
- Regulating Advertising of Health Products
- Regulating health products
- Regulatory Requirements for Advertising